Genes and primary headaches: discovering new potential therapeutic targets

Migraine and cluster headache have long been considered vascular disorders. Even if the so-called “vascular theory” of migraine has been shown to be inadequate in explaining the complex symptoms of the disorder, both migraineurs and cluster headache patients show abnormalities in both cranial and extracranial vascular reactivity [14, 15]. In addition, both disorders are characterized by a significant comorbidity with diseases such as stroke, myocardial infarction, hypertension and Raynaud’s phenomenon [16‐18]. Several genes involved in vascular functions, such as endothelin-1 (ETA-1), angiotensin-converting enzyme (ACE), Neurogenic Locus Notch Homolog Protein 4 (NOTCH4) and methylenetetrahydrofolate reductase (MTHFR) genes have been studied in patients with primary headaches and some of these, such as the MTHFR gene, were significantly associated with migraine [19‐24].

The MTHFR gene is located on chromosome 1p36.3; it consists of 11 exons and encodes for the methylenetetrahydrofolate reductase, a crucial enzyme involved in purine and thymidylate biosynthesis, methylation of DNA and amino acids, and neurotransmitters synthesis. The MTHFR enzyme catalyzes the reduction of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a substrate needed for the conversion of homocysteine to methionine (Figure 1). This pathway is folate-dependent and a lack of dietary folate can produce an increase in homocysteine levels. The clinical consequences of increased homocysteine plasma concentrations include endothelial cells injury and alterations in coagulant properties of blood [25‐27]. Furthermore, homocysteine derivatives act as NMDA receptor agonists and they may enhance glutamatergic neurotransmission, thereby increasing the spontaneous trigeminal cells firing and predisposing cortical neurons to hyperexcitability [28, 29].

Several genetic variants have been described in the MTHFR gene. Genetic research investigating the role of MTHFR in primary headaches has focused almost exclusively on two common polymorphisms, due to their functional activity. These are a cytosine (C) > thymine (T) change at position 677 in exon 4, that results in a substitution of an alanine into a valine amino acid (Ala222Val) in the catalytic domain, and an adenine (A) > cytosine (C) change occurring at position 1298 in exon 8, that changes a glutamate into an alanine amino acid (Glu429Ala). The C677T genetic variant allele produces a 35% reduction of MTHFR enzyme activity whereas the A1298C variant results in decreased MTHFR activity to a somewhat lesser degree [30]. These two variants have been extensively associated with the pathogenesis of several disorders, such as cardiovascular disease, cerebrovascular disease, and psychiatric disorders [31‐35].

A large number of studies also provided evidence of an association between migraine and the C677T polymorphism in the MTHFR gene [22‐24]. This association seems significant mainly in patients affected by migraine with aura (MA) while in patients affected by migraine without aura (MO) the results are conflicting. Two recent genetic meta-analysis provided clear evidence of a significant association between MA and the MTHFR gene: the carriage of the T allele was shown to be associated with an approximately two-fold increased risk [36, 37].

More recently, in Norfolk Island Population, three MTHFR single nucleotide polymorphisms (SNPs) were associated with migraine. These three SNPs are located in intron 7 (rs6696752), in the 3′ untranslated region (rs4846048), and in exon 11 (rs2274976, non synonymous, producing a substitution of arginine to glutamine, R594Q) and have not previously been reported to show any genetic association with migraine. These findings reinforced the potential role of MTHFR in migraine susceptibility [37].

A recent case–control study examined the association between MTHFR polymorphisms and cluster headache in a group of 147 cases and 599 Caucasians controls. This study found no evidence of association between genotypes of the MTHFR 677C>T polymorphism and cluster headache overall. However, subgroup analyses suggested that carriers of the MTHFR 677 T allele may have an increased risk for chronic cluster headache, suggesting a need for additional studies in order to evaluate a possible role of MHTFR as modifier gene in the disorder [38]. At present, no study examined the potential association between tension-type headache and MTHFR polymorphisms.

Hyperomocysteinemia has been reported in patients with migraine [39]. Folic acid, vitamin B6 and vitamin B12 supplementation has been found to be effective in reducing the occurrence of migraine attacks [40]. Therefore, a recent pharmacogenetic study evaluated the effects of different MTHFR and 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR) genotypes on the occurrence of migraine in a double-blinded placebo-controlled trial of daily vitamin B supplementation. Patients carrying the C allele of the MTHFR C677T variant showed a higher reduction in homocysteine levels, severity of pain and migraine disability, when compared with those with the T allele. MTRR catalyzes the remethylation of homocysteine to methionine, and, similarly, the A allele carriers of the MTRR A66G variants showed a higher degree of reduction in homocysteine levels, severity of pain and percentage of severe migraine disability, when compared with those carrying the GG genotypes [41]. This pivotal study suggests that both MTHFR and MTRR gene variants may influence the response to treatment with vitamin B in migraineurs. Conversely, genetic data concerning the role of vascular genes in tension-type headache are still scarce. A recent meta-analysis investigated the genetic role of the endothelin type A receptor (EDNRA) – one of the two receptors of the potent vasoconstrictor ETA-1 – in migraineurs and in patients with tension-type headache [42]. This meta-analysis included 440 migraineurs, 222 patients with tension-type headaches and 1323 controls from three previous studies reporting conflicting results about EDNRA -231G>A polymorphism. It found a significant difference in the frequency of AA genotype between migraine subjects and healthy controls. However, no differences were found in the distribution of the EDNRA -231G>A SNP between patients with tension-type headaches and controls.

Several clinical and experimental data support the concept of abnormal cortical excitability as the pivotal physiological disturbance in migraine [43, 44]. Mutations in genes that code for ion channels or pumps (CACNA1A, ATP1A2, and SCN1A) have been described in FHM, strongly supporting the hypothesis that migraine may be classified as a “cerebral ionopathy” [45]. Ca_V 2.1 (CACNA1A) calcium channels are located in the presynaptic terminal of both excitatory and inhibitory neurons, Na_V 1.1 (SCN1A) sodium channels are expressed in inhibitory interneurons while Na⁺/K⁺ATPase (ATP1A2) is located at the surface of glial cells (astrocytes). Knock-in mouse models carrying such mutations showed an increased susceptibility to cortical spreading depression, the likely underlying mechanism of migraine aura [46, 47]. Finally, an interesting comorbidity between migraine and epilepsy has been described, further supporting a role for ion homeostasis genes in migraine pathophysiology [48, 49]. However, until few years ago, no ion channel gene involvement has been described in the common form of migraine or in other primary headaches disorders.

In 2010, a frameshift mutation in the KCNK18 gene which segregates perfectly with typical MA in a large, multigenerational pedigree was reported [50]. This gene codes for TWIK-related spinal cord potassium channel (TRESK), a member of the two-pore domain (K2P) potassium channel family. Functional characterization of the F139WfsX24 mutation demonstrated that it causes a complete loss of TRESK function and that the mutant subunit suppresses the wild-type channel function through a dominant-negative effect.

The KCNK18 gene is located on chromosome 10; it encodes a protein containing 4 transmembrane domains (TMDs), and two pore-forming domains. The extracellular domain located between TMD1 and TMD2 contains a conserved cysteine residue that may form a disulfide bridge to aid channel dimerization, and a conserved N-linked glycosylation site, important for surface expression of the channel [51]. In humans, the family of KP2 channels includes 15 related channels but TRESK is unique in having a large intracellular regulatory domain located between TMD2 and TMD3. TRESK is abundantly expressed in the dorsal root ganglion (DRG), and in other sensory ganglia such as the trigeminal ganglion (TG). TRESK was also found in human autonomic nervous system ganglia, such as the stellate ganglion and paravertebral sympathetic chain [50, 52].

The TRESK is an outwardly rectifying K⁺ current channel that contributes to the resting potential and is the most important background potassium channel in DRG. TRESK is activated in a complex manner by intracellular calcium signalling. The calcium/calmodulin-dependent protein phosphatase, calcineurin, activates TRESK function [53, 54]. Calcineurin also regulates nuclear factor of activated T cells (NFATs), transcription factors that regulate inducible expression of many cytokines. In addition, recent studies have identified volatile anesthetics as highly potent TRESK agonists, interacting directly with the channel. On the contrary, cyclosporin A and tacrolimus, two potent immunosuppressants that specifically inhibit the calcineurin activation of NFATs, mimic a TRESK loss of function by keeping the channel insensitive to increases in intracellular Ca2⁺.

The physiological functions of TRESK have been mainly investigated in knock-out (KO) mice. The KO mice show no gross anatomical or behavioral phenotype. The gene ablation has minimal effect on the resting membrane potential. However, DRG neurons from TRESK KO mice displayed a lower threshold for activation, reduced action potential duration, and slightly higher amplitudes of after-hyperpolarization, suggesting that DRG neurons from KO mice were more excitable than wild-type DRG neurons [55]. In addition, due to the coupling of TRESK to the histamine H₁ receptor, the channel may reduce neuronal excitability in inflammatory conditions when histamine or other inflammatory modulators are released into the surrounding tissue. Taken together, these data suggest an important role of TRESK in both acute and chronic pain conditions [56].

After the identification of KCNK18 gene mutation in a Canadian MA pedigree, a large cohort of unrelated MA patients and healthy controls was screened for gene mutation. Several missense variants (R10G, A34V, C110R, S231P and A233V) were found. These variants either had no apparent functional effect, or they caused a reduction in channel activity. The A34V was identified in a single Australian migraine proband for which family samples were not available, but it was not detected in controls. By contrast, the R10G, C110R, and S231P variants were found in both migraineurs and controls. The authors concluded that the presence of a single non-functional variant in the KCNC18 gene is probably not sufficient to determine whether an individual develops migraine [57].

In a recent study, we examined the presence of KCNK18 gene mutations in a large data set of Italian migraine patients (both with MA and MO) and healthy controls. We confirmed the presence of KCNK18 gene mutations in MA and also found gene mutations in MO patients [58]. Some of these gene variants have not previously been described. However, the functional relevance of these mutations still need further investigations. Finally, KCNK18 gene involvement in tension-type headache or cluster headache has not been investigated yet.

The TRESK K2P channel is a novel and interesting component of the migraine pathogenesis pathway and represents an excellent opportunity for development of antimigraine therapy, given its highly selective expression pattern in neuronal structures, which is known to be important in disease pathogenesis. Its highly specific expression pattern in TG, DRG and parasympathetic neurons and the presumed role in abating neuronal excitability under inflammatory conditions make it an excellent target for development of new migraine therapeutics [59, 60]. Specific agonists could upregulate TRESK activity and may have a potential in both acute and preventive migraine therapy, as well as in other pain disorders.

Recently, the transient receptor potential (TRP) channels gained increased interest for their potential involvement in primary headaches [61, 62]. There are at least 30 members of the mammalian TRP family, which are coded by several, different genes. TRP channels are distributed in many peripheral tissues as well as central and peripheral nervous system. Several TRP family members, including the TRPV1 (Transient Related Potential Vanilloid Type 1), TRPV2 (Transient Related Potential Vanilloid Type 2), TRPV3 (Transient Related Potential Vanilloid Type 3) and TRPV4 (Transient Related Potential Vanilloid Type 4), TRPM8 (Transient Related Potential Metastatin Type 8) channels, are polymodal sensors expressed in the sensory neurons of dorsal root ganglia (DRG) and trigeminal ganglia (TG) [63]. In particular, TRPV1 receptor is highly co-expressed with calcitonin-gene related peptide (CGRP) a potent vasodilator with an important role in migraine. TRPV1 is also co-expressed with other pain signalling molecules such as substance P, P2X3 purinergic receptors and other markers of nociceptive C and Aδ fibers [64]. It has been proposed to play a crucial role as mediators of neuropathic pain and have been proposed to play a role in migraineous allodynia and sensitization phenomena [65].

Using a genetic association strategy, in 2012 Carreno et al. found a significant association between SNPs within the TRPV1 and TRPV3 genes and migraine in the Spanish population [66]. Interestingly, TRPV1 and TRPV3 are located in close proximity on the 17p13 chromosomal region and they share a high sequence homology. In the meanwhile, two genome-wide association studies (GWAS) found evidence of a significant association between genetic markers in or near the TRPM8 gene and migraine [67, 68]. TRPM8 gene is expressed by a different TRPV1-negative neuronal subpopulation in DRG and TG. These preliminary data significantly support a role for TRP channels in the pathogenesis of primary headaches.

TRP channels have been among the most aggressively pursued drug targets over the past few years and several studies suggested these channels as potential therapeutic targets in migraine. Both peripheral and central nerve terminals at the spinal cord can be targeted to induce pain relief by TRPV1 agonists. In particular, the analgesic effects of the TRPV1 antagonist SB-705498 on trigeminovascular sensitization and neurotransmission have been studied in an animal model of neurovascular head pain [69, 70]. Recently, a phase II clinical trial using SB-705498 has been conducted for the acute treatment of migraine attacks but results are pending (ClinicalTrials.gov).

A large number of endocrine abnormalities has been described in patients with primary headaches [71, 72]. The hypothalamus, with its paramount control of the endocrine system, as well as its widespread connections with both central and autonomic nervous system, exerts a pivotal role in the pathogenesis of both migraine and cluster headache [73]. Therefore, genes that code for proteins involved in endocrine functions are candidate genes for primary headache disorders. Polymorphisms in genes that code for estrogen and progesterone receptors have been intensively studied in migraineurs, with contrasting results [74, 75].

In 1998, two research groups independently discovered a new hypothalamic peptidergic system. The former group named the peptides “hypocretins”, because of their hypothalamic location and structural similarity to the incretin family of hormones [76]. The latter group named the peptides “orexins”, due to the appetite-enhancing properties when administered centrally to rats [77].

Subsequent studies revealed complex and interesting neurobiological effects of these peptides, with particular relevance to the pathophysiology of primary headaches [78].

The hypocretins (Hcrt-1 and Hcrt-2), also called orexins, are peptides derived by proteolytic cleavage from the same 130 amino acid precursor peptide (prepro-hypocretin). A single gene located on chromosome 17q21 in humans is responsible for encoding prepro-hypocretin. The human prepro-hypocretin gene consists of 2 exons and 1 intron. The hypocretins bind to 2 G-protein coupled receptors, termed HCRTR1 and HCRTR2. The HCRTR1 gene in humans is located on chromosome1p33 whereas the HCRTR2 gene is located on chromosome 6p11. Both genes consist of 7 exons and 6 introns. Hcrt-1 has equal affinity for both HCRTR1 and HCRTR2, with Hcrt-2 demonstrating a 10-fold higher affinity for HCRTR2 than HCRTR1. Activation of both receptors results in elevated levels of the intracellular Ca²⁺ concentrations, and this in turn results in the enhancement of the Gq-mediated stimulation of phospholipase C. Hypocretin immunoreactive cell bodies have been observed mainly in the hypothalamus [79]. Hypocretin-containing neurons have widespread projections throughout the CNS with particularly dense excitatory projections to monoaminergic and serotonergic brainstem centers [80]. The hypocretin system influences a wide range of physiological processes in mammals, such as feeding, arousal, rewards, and drug addiction [81, 82]. Recently, a number of studies in experimental animals showed that hypocretins are involved in pain modulation within the CNS, and suggested an important role for these peptides in primary headaches [83].

In 2004, our research group investigated the possible involvement of the hypocretin transmission in cluster headache. We selected several DNA polymorphisms of the three genes that constitute the hypocretin system and, using a case–control strategy, we evaluated possible allelic and genotypic differences in a group of 109 CH patients and 211 controls. Genetic analysis revealed that both allelic and genotypic frequencies of the G1246A polymorphism in the HCRTR2 gene were significantly different between CH patients and controls [84]. Subjects homozygous for the G allele, in comparison with the remaining genotypes, were 5-fold more likely to develop the disease. This association was confirmed in a large group of CH patients and controls from Germany [85]. On the contrary, Baumber et al. found no association between CH and the HCRTR2 gene in a cohort of 259 patients of Danish, Swedish, and British origin [86]. To resolve this issue, we performed a genetic meta-analysis of the previous studies (593 cases and 599 controls) and a haplotype analysis: both these studies confirmed the presence of a significant association between the HCRTR2 gene and CH [87]. At present, the possible involvement of the hypocretin system in migraine has been scarcely investigated. Studies in CH patients prompted two independent research groups to evaluate the association of the G1246A polymorphisms in the HCRTR2 gene with migraine. Both studies found no association between this polymorphism and migraine or its clinical subtypes [88, 89]. Recently, we performed a genetic case–control study to investigate whether genetic variants in the HCRTR1 gene could modify the occurrence and the clinical features of migraine. Using a case–control strategy we genotyped 384 migraine patients and 259 controls for three SNPs in the HCRTR1 gene. Genotypic and allelic frequencies of the rs2271933 non-synonymous polymorphism were different between migraineurs and controls [90]. The carriage of the A allele was associated with an increased migraine risk. This study supports the hypothesis that the HCRTR1 gene could represent a genetic susceptibility factor for migraine and suggests that the hypocretin system may have a role also in the pathophysiology of migraine. Unfortunately, no data regarding involvement of HCRTR genes in tension-type headache are currently available.

The growing knowledge concerning the role of hypocretins/orexins in different neurological conditions has generated considerable interest in developing small-molecule hypocretin receptor antagonists as a novel therapeutic strategy. Hypocretin antagonists, especially those that block Hcrtr1 or both Hcrtr1 and Hcrtr2 receptors, have been studied mainly as new drugs for sleep disorders. In experimental animals hypocretin/orexin antagonists (almorexant, suvorexant) clearly promote sleep, and clinical results are encouraging [91‐94]. Considering the high frequency of sleep disorders occurring in patients with migraine and CH, these drugs offer a new perspective in the treatment of these disorders. Finally, a pivotal role for these peptides in drug reward and drug seeking has been established and their potential role as anti-relapse medication in drug addiction is currently under investigation in experimental animals [95].